NEW YORK (GenomeWeb News) – French biotech firm IntegraGen today reported a 14 percent revenue increase year over year for full-year 2010.
For the year, the company reported €3.3 million ($4.8 million) in total revenues, up from €2.9 million in 2009. The company had sales of €3.2 million in 2010, also a 14 percent increase from €2.8 million a year ago. The company also recorded about €102,000 in other income, up 9 percent from €94,000 in 2009.
IntegraGen's genomics services business posted €3.2 million in sales. Within that segment, its high-throughput sequencing business saw the biggest year-over-year bounce as it accounted for 25 percent of total sales in 2010, compared to 4 percent in 2009.
Medium-throughput genotyping was 10 percent of IntegraGen's total business, while high-throughput genotyping made up 65 percent of the firm's total revenues.
The company has two other businesses, its autism program and oncology program. In autism, its commercial partner Transgenomic launched the ARISk Familial Autism Panel based on IP licensed from IntegraGen in June. IntegraGen also inked a joint ownership and exclusive licensing deal with the Johns Hopkins University and Massachusetts General Hospital covering the diagnostic use of a biomarker related to the JARID 2 gene.
In oncology, the company and the French National Institute for Health and Medical Research began collaboration on the development of genetic diagnostics for hepatocellular carcinoma.
IntegraGen reported that its R&D costs remained "stable" in 2010 at €1.4 million. Payroll costs rose 6 percent to €1.8 million from €1.7 million.
The firm's net loss for the year climbed to €2.9 million from €2.7 million, a 7 percent increase.
As of Dec. 31, 2010, IntegraGen had €6 million in cash and cash equivalents. The company had a €6.7 million private placement prior to going public in June, when it began trading on the New York Stock Exchange's Alternext market.